Order Article Reprints

Pal P, Millner A, Semina SE, Huggins RJ, Running L, Aga DS, Tonetti DA, Schiff R, Greene GL, Atilla-Gokcumen GE, et al. Endocrine Therapy-Resistant Breast Cancer Cells Are More Sensitive to Ceramide Kinase Inhibition and Elevated Ceramide Levels Than Therapy-Sensitive Breast Cancer Cells. Cancers. 2022; 14(10):2380. https://doi.org/10.3390/cancers14102380

Pal, Purab, Alec Millner, Svetlana E. Semina, Rosemary J. Huggins, Logan Running, Diana S. Aga, Debra A. Tonetti, Rachel Schiff, Geoffrey L. Greene, G. Ekin Atilla-Gokcumen, and et al. 2022. "Endocrine Therapy-Resistant Breast Cancer Cells Are More Sensitive to Ceramide Kinase Inhibition and Elevated Ceramide Levels Than Therapy-Sensitive Breast Cancer Cells" Cancers 14, no. 10: 2380. https://doi.org/10.3390/cancers14102380

Pal, P., Millner, A., Semina, S. E., Huggins, R. J., Running, L., Aga, D. S., Tonetti, D. A., Schiff, R., Greene, G. L., Atilla-Gokcumen, G. E., & Frasor, J. (2022). Endocrine Therapy-Resistant Breast Cancer Cells Are More Sensitive to Ceramide Kinase Inhibition and Elevated Ceramide Levels Than Therapy-Sensitive Breast Cancer Cells. Cancers, 14(10), 2380. https://doi.org/10.3390/cancers14102380